Are liquid biopsies a surrogate for tissue EGFR testing?

Abstract

Molecular profiling has changed the treatment landscape in advanced non-small-cell lung cancer. Accurately identifying the tumours that harbour sensitizing EGFR mutations, the most common targetable molecular alteration, as well as those with acquired resistance mutations (e.g. T790M) on treatment is a high clinical priority. The current clinical gold… (More)
DOI: 10.1093/annonc/mdx706

Topics

  • Presentations referencing similar topics